Hybrid cis-stilbene Molecules: Novel Anticancer Agents

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Pharmacology

Background:

• Increasing interest in anticancer hybrids has led to numerous reports on their design, synthesis, and bioevaluation.
• Novel multi-target-directed drug candidates have been synthesized and their biological activities evaluated.
• Hybrid compounds incorporate diverse molecular scaffolds, including stilbenes, aromatic quinones, and various heterocycles.

Purpose of the Study:

• To review studies on bioactive hybrid molecules derived from combretastatin A-4 and its analogs.
• To discuss the design, synthesis, and bioevaluation of these novel anticancer agents.
• To explore the anticancer mechanisms and structure-activity relationships of selected hybrids.

Main Methods:

• Literature review of studies on anticancer hybrid compounds.
• Analysis of hybrid designs incorporating natural compounds like Resveratrol, curcumin, coumarin, and oleanolic acid.
• Examination of hybrids built with stilbenes, aromatic quinones, and heterocyclic moieties (benzimidazole, imidazole, pyrimidine, pyridine, pyrazole, quinoline, quinazoline).

Main Results:

• Numerous novel multi-target-directed anticancer drug candidates have been synthesized and evaluated.
• Hybrid compounds combining combretastatin A-4 or its analogs with other pharmacologically active entities have been developed.
• The review discusses the anticancer mechanisms and structure-activity relationships of these selected hybrids.

Conclusions:

• Anticancer hybrid compounds, particularly those based on combretastatin A-4, represent a promising area of drug discovery.
• The strategic combination of different pharmacophores in hybrid molecules can lead to potent multi-target-directed anticancer agents.
• Understanding structure-activity relationships is crucial for the rational design of effective anticancer hybrids.